Get the Stockscreener App
7.00
4.63%
0.31
After Hours:
6.69
-0.31
-4.43%
Tvardi Therapeutics Inc stock is traded at $7.00, with a volume of 1.78M.
It is up +4.63% in the last 24 hours and down -79.34% over the past month.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
See More
Previous Close:
$6.69
Open:
$6.65
24h Volume:
1.78M
Relative Volume:
10.99
Market Cap:
$65.64M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-82.62%
1M Performance:
-79.34%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.15
$7.1167
1-Week Range:
$5.65
$43.65
52-Week Range:
$5.65
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
7.00 | 390.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
What dividend safety score for Tvardi Therapeutics Inc. stockJuly 2025 Sentiment & Community Verified Trade Alerts - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsTrade Risk Assessment & Daily Volume Surge Trade Alerts - newser.com
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - TradingView
Tivardi downgraded at Raymond James following TTI-101 trial failure - Seeking Alpha
Raymond James downgrades Tvardi Therapeutics stock rating after failed trial - Investing.com India
Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks - Sahm
Tvardi Therapeutics Faces Setback in Phase 2 Trial - TipRanks
Tvardi Therapeutics, Inc. Updates on Phase 2 REVERT Trial Results - TradingView
Optimistic Buy Rating for Tvardi Therapeutics: Promising Potential of TTI-109 Amidst TTI-101 Setbacks - TipRanks
What indicators show strength in Tvardi Therapeutics Inc.2025 Technical Overview & Stock Portfolio Risk Management - newser.com
Best data tools to analyze Tvardi Therapeutics Inc. stockBear Alert & Momentum Based Trading Ideas - newser.com
Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results - Yahoo Finance
Measuring Tvardi Therapeutics Inc.’s beta against major indicesJuly 2025 Big Picture & Technical Buy Zone Confirmations - newser.com
Tvardi Therapeutics (NASDAQ:TVRD) Price Target Cut to $15.00 by Analysts at BTIG Research - Defense World
Can swing trading help recover from Tvardi Therapeutics Inc. lossesStop Loss & Verified Short-Term Trading Plans - newser.com
Can Early REVERT Data Shape Tvardi Therapeutics' (TVRD) Path in the Pulmonary Fibrosis Market? - simplywall.st
Tvardi Therapeutics (NASDAQ:TVRD) Trading Down 83.9% on Analyst Downgrade - Defense World
BTIG Maintains Tvardi Therapeutics (TVRD) Buy Recommendation - Nasdaq
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - The AI Journal
Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays - TipRanks
Tvardi Therapeutics: 'Sell' Rating On IPF Drug TTI-101 Advancement Uncertainty (TVRD) - Seeking Alpha
Tvardi Therapeutics stock plummets as Oppenheimer slashes price target By Investing.com - Investing.com Australia
BTIG lowers Tvardi Therapeutics stock price target to $15 on IPF trial setback - Investing.com India
Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge - Benzinga
TVRD: Analyst BTIG Lowers Price Target Significantly | TVRD Stoc - GuruFocus
Tvardi Therapeutics stock plummets as Oppenheimer slashes price target - Investing.com
Tvardi drops dramatically on phase II rare lung disease data - BioWorld MedTech
Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’ - TipRanks
Live market analysis of Tvardi Therapeutics Inc.2025 Risk Factors & Real-Time Stock Entry Alerts - newser.com
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? - Menafn.com
Tvardi's STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rates - Fierce Biotech
Barclays Initiates Tvardi Therapeutics at Overweight With $61 Price Target - MarketScreener
Barclays initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com Nigeria
Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today? - TipRanks
Does Tvardi Therapeutics Inc. stock trade at a discount to peersJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
Using AI based signals to follow Tvardi Therapeutics Inc.Quarterly Profit Summary & Smart Allocation Stock Reports - newser.com
Tvardi Therapeutics' Potential Lung Disease Treatment Fails to Meet Goals; Shares Decline Pre-Bell - MarketScreener
Published on: 2025-10-13 07:20:38 - newser.com
Using RSI to spot recovery in Tvardi Therapeutics Inc.2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
Tvardi Therapeutics stock plunges after failed IPF trial data By Investing.com - Investing.com Nigeria
Tvardi Therapeutics stock plunges after failed IPF trial data - Investing.com
Using data models to predict Tvardi Therapeutics Inc. stock movement2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26% - Yahoo Finance
Tvardi Therapeutics Inc. stock volume spike explainedJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Published on: 2025-10-10 08:50:26 - newser.com
Tvardi Therapeutics Inc. stock daily chart insightsJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Is Tvardi Therapeutics Inc 69C a good long term investmentStock Rotation Strategies & Get Tomorrow’s Winners Today With AI - earlytimes.in
Published on: 2025-10-06 07:23:43 - newser.com
Order flow analysis tools used on Tvardi Therapeutics Inc.July 2025 Short Interest & Weekly Stock Performance Updates - newser.com
Is it time to cut losses on Tvardi Therapeutics Inc.Trade Exit Summary & Entry Point Confirmation Alerts - newser.com
Will Tvardi Therapeutics Inc. (69C) stock beat value stocks2025 Market Trends & Weekly Watchlist for Hot Stocks - newser.com
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
There is no financial data for Tvardi Therapeutics Inc (TVRD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Tvardi Therapeutics Inc Stock (TVRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):